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OBJECTIVE: A multifaceted quality improvement programme for the care of diabetes was 
implemented in two different Flemish regions (Aalst and Leuven) and with slightly 
different modalities. The overall objective of the programmes was to improve adherence 
to evidence-based guidelines on diabetes in primary care physicians. The aim of this 
study was to assess the cost-effectiveness of the programmes compared to regular care 
in both regions. 
METHODS: Short-term effects of the programmes were extrapolated to long-term hard 
endpoints, using the validated UKPDS Outcomes Model, supplemented by 2 self 
developed Markov models to account for benefits on process parameters (screening for 
retinopathy and nephropathy). A simulation of the evolution of patients was made over a 
time horizon of 25 years with cycles of 1 year, from a public health care payer 
perspective. Cost data of the different disease states and extra direct medical costs due 
to intensified patient management were collected from literature and from the National 
Institute for Health and Disability Insurance. For the self developed Markov models, 
utility data for all states were obtained from published studies and transition probabilities 
were obtained from local epidemiological studies and published trials. In the simulation 
the intervention was assumed to be implemented three times over the predicted life 
expectancy. Deterministic sensitivity analyses were performed on the combined results of 
outcome and process parameters. 
RESULTS: At a cost of intervention of €185 (Aalst) and €284 (Leuven) per patient, the 
analyses show ICER’S for Aalst and Leuven of respectively €15206.70/QALY and 
€10397.96/QALY. Sensitivity analyses show few influence of changed input variables. 
CONCLUSION: When using a ratio of €30,000/QALY as threshold of willingness to pay for 
health gain, the diabetes health care programmes have an acceptable ICER in both 
regions. 
 
